J Korean Surg Soc.
1998 Nov;55(5):653-661.
Prognostic Value of Angiogenesis in Breast Cancer
- Affiliations
-
- 1Departments of Surgery, Kang Dong Sacred Heart Hospital, Hallym University Medical College.
- 2Departments of Pathology, Kang Dong Sacred Heart Hospital, Hallym University Medical College.
Abstract
-
BACKGROUND: There is considerable experimental evidence to indicate that tumor growth is dependent
on angiogenesis. To investigate how tumor angiogenesis correlates with clinical factors and prognosis
in breast carcinoma, we counted microvessels (capillaries and venules) and graded the density of micro
vessels within the invasive ductal carcinomas of 59 patients.
METHODS
Using light microscopy, we highlighted the vessels by staining their endothelial cells immu
nohistochemically for rabbit antihuman factor-VIII related antigen (Dako L1809, USA). The microvessels
were carefully counted (per 200 field) in the most active areas of neovascularization without knowledge
of either the outcome in the patient or the clinical variables.
RESULTS
The mean age was 47.8 years. There was no statistical correlation between angiogenesis and
either estrogen receptor status or age. However, there was a statistical correlation with tumor size (p< or =0.05). There was a statistical difference between lymph-node-metastasis positive group and negative group
(p= 0.006). Angiogenesis correlated statistically with TMN stage (microvessels count:stage I= 31.27,
stage II= 40.74, and stage III= 78.9)(p= 0.001). There was a statistical correction between angiogenesis
and follow-up results (microvessels counts:disease free group= 42.11, living metastatic group= 63.64,
and expired group= 73.60)(p= 0.031).
CONCLUSIONS
In this study, the degree of angiogenesis (the number of microvessels per 200 field
in the area of most intensive neovascularization) may have a predictive value in invasive breast carci
nomas. Therefore, assessment of tumor angiogenesis may give us useful information for selecting thera
peutic and follow-up plan for patients with breast carcinomas.